A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

Chronic Obstructive Pulmonary Disease COPD Clinical Trial

Official title:
A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients With a History of Frequent Acute Exacerbations While on Maintenance Therapy

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether AZD7624 can reduce acute Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients on COPD maintenance therapy with a history of frequent acute exacerbations.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Obstructive Pulmonary Disease COPD
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive

Clinical Trial Details

NCT number	NCT02238483
Study type	Interventional
Source	AstraZeneca
Contact
Status	Completed
Phase	Phase 2
Start date	October 28, 2014
Completion date	April 4, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03162055` - Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease	Phase 3
Completed	`NCT03131362` - Realize the Current Situation of COPD Patients in China
Completed	`NCT01682447` - Pulmonary Rehabilitation: Effects on Cognitive Functioning, Mood, Anxiety, and Quality of Life in Patients With COPD	N/A
Completed	`NCT02645253` - A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men	Phase 1
Completed	`NCT02971293` - Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871	Phase 2